The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left more money in people’s wallets. Lighter passengers are saving airlines 100 million litres of fuel each year. And billions of people are enjoying a better quality of life, with improvements to their mental and physical health.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,

Leigh-Anne Lagden was given a free weight loss injection in exchange for social media promotion but claims they told her to take five times as much as she should have and she ended up hospitalized.

What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An imbalance in this process, leading to poor repair of DNA, is one of the hallmarks of ageing.

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025. It reported strong quarterly earnings.